Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Baker Hughes Co (BKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Baker Hughes Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Baker Hughes Co trades at $57.49 (market cap $54.04B). The key difference: Baker Hughes Co is far larger — about 12× ACADIA Pharmaceuticals Inc.'s market cap, and Baker Hughes Co pays a 1.69% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BKR | |
|---|---|---|
Market Cap | $4.49B | $54.04B |
Sector | Health | Energy |
52-Week High | $28.06 | $69.67 |
52-Week Low | $20.06 | $38.68 |
Enterprise Value | $3.69B | $55.44B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Baker Hughes (BKR) trades at $54.47, up 3.2% over the past 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Recent contract wins in Angola and Nigeria, along with expansion into geothermal energy, highlight growth initiatives. Financials show strong profitability with an 11.17% net income margin and improving cash flow trends, though revenue growth has moderated.
The outlook for BKR is positive, supported by analyst consensus with a $74.27 price target and 66.7% buy ratings. Key opportunities include energy transition projects and international contracts, while risks involve oil price volatility and integration challenges from the Chart Industries acquisition. The stock presents a value opportunity with a P/E of 17.01, trading below analyst targets amid operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
